Dosing & Efficacy

Nasacort® Allergy 24HR

Dosing Information—
Adults and Children

Nasacort® is indicated to treat allergic rhinitis in adults and children 2 years of age and older. It is the only OTC INS to be proven safe for children as young as 2.

Nasacort® Allergy 24HR Dosing Chart for Adults and Children

It may take up to 1 week of daily use to feel the most symptom relief.

Nasacort® is recommended for daily use, but adult supervision is required. Please consult with your physician if your child needs to use Nasacort® for more than 2 months.

For complete directions, warnings, and other information, please see the Drug Facts Label.

aThe growth rate of some children may be slower while using this product. If children need to use Nasacort® for longer than 2 months a year, they should see a doctor.
bAn adult should supervise use.

Use only as directed.

How to use Nasacort®

Get the simple steps for using Nasacort®.

Proven Efficacy at Dose 1

In a clinical study of 429 patients with seasonal rhinitis, patients taking Nasacort® Allergy 24HR saw 25% relief of nasal symptoms starting at Day 1.1,2,*

DAY 1a
OVERALLb(POST-TITRATION)
25%reliefc
8%
53%reliefc
20%
Relief begins
on Day 1

A randomized, placebo-controlled, double-blind, 3-week study to investigate the efficacy and safety of once-daily Nasacort® AQ. Symptom severity of each individual component of the nasal index was assessed on a scale from 0 (absent) to 3 (severe). Patients randomized to the Nasacort® AQ group received 220 mcg/day for the first week of treatment and either 220 mcg/day (n=145) or 110 mcg/day (n=142) for the remainder of the study; 142 patients received placebo.1


*It may take up to 1 week of daily use to feel the most symptom relief.

aMeasured before second dose.
bMeasured over the last 2-week (post-titration) periods.
cNasal index is the sum of congestion, nasal discharge, and sneezing.

References: 1. Settipane G, Korenblat PE, Winder J, et al. Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Clin Ther. 1995;17(2):252-263. 2. Data on file. Sanofi-aventis U.S.

Use only as directed.

Continuous Relief of Nasal Allergy Symptoms Over 12 Months1

In a clinical study of 172 patients with persistent allergic rhinitis, Nasacort® provided powerful relief of allergy symptoms from month 1 through 12.

Continuous Relief of Nasal Allergy Symptoms Over 12 Months chart

Reference: 1. Koepke JW, Beaucher WN, Kobayashi RH, et al. Long-term safety and efficacy of triamcinolone acetonide aqueous nasal spray for the treatment of perennial allergic rhinitis. Allergy Asthma Proc. 1997;18(1):33-37.

Use only as directed.

Effective Nasal Allergy Symptom Relief in Children Ages 2 to 51

In the largest published study of any intranasal corticosteroid, designed specifically to assess both the safety and efficacy of Nasacort® vs placebo in children 2 to 5 years of age with perennial allergic rhinitis, Nasacort® was shown to provide effective relief from nasal allergies.1

Nasacort® improved patients’ instantaneous Total Nasal Symptom Score by 30%, compared to 25% with placebo.1

Effective relief of nasal allergy symptoms in children 6 to 11 years of age2

42%a
40%a
28%a
38%
37%
25%
44%
40%
29%
44%
42%
31%
Nasal indexb Nasal stuffiness Nasal discharge Sneezing

Mean change in symptom scores: 2

Nasacort® 220 mcg daily=2.50

Nasacort® 110 mcg daily=2.62

Placebo=1.78

The primary efficacy end point was the mean change from baseline in 24-hour reflective nasal index over the 2-week treatment period. Nasal index is the sum of the 3 individual symptom scores. Symptom severity was assessed on a scale from 0 (absent) to 3 (severe)2. See Drug Facts Label for information about pediatric dosing and growth.

aP<0.05 vs placebo.

bNasal index is the sum of congestion, nasal discharge, and sneezing scores.

References: 1. Weinstein S, Qaqundah P, Georges G, Nayak A. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Ann Allergy Asthma Immunol. 2009;102(4):339-347. 2. Schenkel EJ, Gross G, Jacobson K, et al. Triamcinolone acetonide aqueous nasal inhaler for the treatment of spring grass seasonal allergic rhinitis in children. Pediatr Asthma Allergy Immunol. 1997;11(2):129-136.

Use only as directed.